These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

947 related items for PubMed ID: 17453373

  • 1. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G, Terpos E.
    Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
    [Abstract] [Full Text] [Related]

  • 2. Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid.
    Mountzios G, Terpos E, Syrigos K, Papadimitriou C, Papadopoulos G, Bamias A, Mavrikakis M, Dimopoulos MA.
    Transl Res; 2010 May; 155(5):247-55. PubMed ID: 20403580
    [Abstract] [Full Text] [Related]

  • 3. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
    Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF, Dimopoulos MA, Rahemtulla A.
    Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
    [Abstract] [Full Text] [Related]

  • 4. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer.
    Mikosch P, Igerc I, Kudlacek S, Woloszczuk W, Gallowitsch HJ, Kresnik E, Stettner H, Grimm G, Lind P, Pietschmann P.
    Eur J Clin Invest; 2006 Aug; 36(8):566-73. PubMed ID: 16893379
    [Abstract] [Full Text] [Related]

  • 5. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.
    Gerontology; 2009 Aug; 55(3):275-80. PubMed ID: 19158438
    [Abstract] [Full Text] [Related]

  • 6. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
    D'Amore M, Fanelli M, D'Amore S, Fontana A, Minenna G.
    Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
    [Abstract] [Full Text] [Related]

  • 7. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
    Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET.
    Cancer Res; 2003 Nov 15; 63(22):7883-90. PubMed ID: 14633717
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data.
    Mountzios G, Ramfidis V, Terpos E, Syrigos KN.
    Clin Lung Cancer; 2011 Nov 15; 12(6):341-9. PubMed ID: 21703936
    [Abstract] [Full Text] [Related]

  • 9. Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.
    Martinetti A, Bajetta E, Ferrari L, Zilembo N, Seregni E, Del Vecchio M, Longarini R, La Torre I, Toffolatti L, Paleari D, Bombardieri E.
    Endocr Relat Cancer; 2004 Dec 15; 11(4):771-9. PubMed ID: 15613451
    [Abstract] [Full Text] [Related]

  • 10. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
    Baek KH, Oh KW, Lee WY, Tae HJ, Rhee EJ, Han JH, Cha BY, Kim YJ, Lee KW, Son HY, Kang SK, Kim CC, Kang MI.
    Bone; 2006 Dec 15; 39(6):1352-60. PubMed ID: 16905375
    [Abstract] [Full Text] [Related]

  • 11. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
    Dougall WC, Chaisson M.
    Cancer Metastasis Rev; 2006 Dec 15; 25(4):541-9. PubMed ID: 17180711
    [Abstract] [Full Text] [Related]

  • 12. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
    Ozkaya O, Buyan N, Bideci A, Gonen S, Ortac E, Fidan K, Cinaz P, Söylemezoğlu O.
    Nephron Clin Pract; 2007 Dec 15; 105(4):c153-8. PubMed ID: 17259742
    [Abstract] [Full Text] [Related]

  • 13. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
    Todenhöfer T, Hennenlotter J, Leidenberger P, Wald A, Hohneder A, Kühs U, Mischinger J, Aufderklamm S, Gakis G, Blumenstock G, Stenzl A, Schwentner C.
    BJU Int; 2014 Jan 15; 113(1):152-9. PubMed ID: 23360112
    [Abstract] [Full Text] [Related]

  • 14. Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation.
    Ricci P, Tauchmanova L, Risitano AM, Carella C, Mazziotti G, Lombardi G, Colao A, Rotoli B, Selleri C.
    Transplantation; 2006 Dec 15; 82(11):1449-56. PubMed ID: 17164716
    [Abstract] [Full Text] [Related]

  • 15. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, Kim SH, Choi YM.
    Menopause; 2008 Dec 15; 15(2):357-62. PubMed ID: 17925661
    [Abstract] [Full Text] [Related]

  • 16. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
    Ostrowska Z, Ziora K, Oświęcimska J, Swiętochowska E, Szapska B, Wołkowska-Pokrywa K, Dyduch A.
    Bone; 2012 Jan 15; 50(1):156-60. PubMed ID: 22001124
    [Abstract] [Full Text] [Related]

  • 17. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
    Ishii R, Morimoto A, Ikushima S, Sugimoto T, Asami K, Bessho F, Kudo K, Tsunematu Y, Fujimoto J, Imashuku S.
    Pediatr Blood Cancer; 2006 Aug 15; 47(2):194-9. PubMed ID: 16358318
    [Abstract] [Full Text] [Related]

  • 18. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A, Schulz H, Emons G, Gründker C.
    Gynecol Endocrinol; 2008 Jun 15; 24(6):331-8. PubMed ID: 18584413
    [Abstract] [Full Text] [Related]

  • 19. Osteoprotegrin and the bone homing and colonization potential of breast cancer cells.
    Kapoor P, Suva LJ, Welch DR, Donahue HJ.
    J Cell Biochem; 2008 Jan 01; 103(1):30-41. PubMed ID: 17471510
    [Abstract] [Full Text] [Related]

  • 20. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Rédini F.
    Bone; 2007 Apr 01; 40(4):981-90. PubMed ID: 17196895
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.